



cancers



an Open Access Journal by MDPI

Treatment-Related Predictive and Prognostic Factors in Lung Cancer

Guest Editors:

Dr. Shinkichi Takamori

Department of Thoracic
Oncology, National Hospital
Organization Kyushu Cancer
Center, 3-1-1 Notame, Minami-ku,
Fukuoka 811-1395, Japan

Dr. Kazuki Takada

Department of Thoracic Surgery,
Kitakyushu Municipal Medical
Center, 2-1-1 Bashaku,
Kokurakita-ku, Kitakyushu,
Fukuoka, Japan

Deadline for manuscript
submissions:

closed (31 January 2022)

Message from the Guest Editors

Lung cancer is a major cause of cancer death worldwide. Surgery is a standard therapy for patients with early-stage lung cancer. Prognostic factors for early-stage lung cancer patients are important for clinicians to determine the postoperative follow-up and to choose patients who should receive the adjuvant chemotherapy. In addition, there have been dramatic pharmacotherapy developments for non-small-cell lung cancer patients; in addition to chemotherapy, molecular-targeted drugs, such as epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors, have been adopted in the clinic. Recently, immunotherapy targeting programmed cell death 1 or programmed death-ligand 1 has gathered great attention as a novel pharmacological treatment. It is important to discover the factors that can be used to select patients who will benefit from such treatments. In this Special Issue, we welcome reports on the treatment-related predictive and prognostic factors in lung cancer.



mdpi.com/si/68049

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)